Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00827697 · ClinicalTrials.gov registry record
A Validation Study for Detecting Chlamydia and Gonorrhea in Rectal Samples
A clinical trial, sponsored by University of Pittsburgh.
- Completed
- Registry status
- 399
- Enrollment target
NCT00827697 is a clinical trial that has completed, run by University of Pittsburgh. The registered enrollment target is 399 participants.
The verdict
NCT00827697 has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- 399 participants
- Enrollment target
Study Summary
Our hypothesis is that nucleic acid amplification testing (NAAT) with the APTIMA Combo2 (AC2) will have greater sensitivity than culture in detecting Neisseria gonorrhoeae in rectal samples. We also hypothesize that AC2 will be equivalent to NAAT with the Becton Dickinson ProbeTec in detecting Chlamydia trachomatis and Neisseria gonorrhoeae in rectal samples.
Interventions
- OTHER Gen-Probe APTIMA Combo2 (AC2)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 399 participants |
| Start Date | 2009-05 |
| Est. Completion | 2010-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00827697
The ClinicalTrials.gov registry entry for NCT00827697 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 399 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Gen-Probe APTIMA Combo2 (AC2) is the first listed.
NCT00827697 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00827697 about?
NCT00827697 is a clinical study titled "A Validation Study for Detecting Chlamydia and Gonorrhea in Rectal Samples". Our hypothesis is that nucleic acid amplification testing (NAAT) with the APTIMA Combo2 (AC2) will have greater sensitivity than culture in detecting Neisseria gonorrhoeae in rectal samples. We also hypothesize that AC2 will be equivalent to NAAT with the Becton Dickinson ProbeTec in detecting Chlam...
What is the current status of trial NCT00827697?
This trial is currently completed. The enrollment target is 399 participants. The study started on 2009-05. Estimated completion is 2010-03.
What interventions are being tested in trial NCT00827697?
The interventions under investigation include: Gen-Probe APTIMA Combo2 (AC2) (OTHER).
Who is sponsoring clinical trial NCT00827697?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.